In a further comparison using DPP-4i/SU as the reference, the GLP-1 RA/SGLT2i combination therapy had the greatest effect in ...

India embraces GLP-1 medications as a major advance in diabetes and obesity care. At AajTak Health Summit, endocrinologist Dr. Ambrish Mithal and Vikrant Shrotriya, Vice President MD, Novo Nordisk ...

The investigational GLP-1 receptor agonist MET-097i, which may be able to be dosed just once a month, yielded weight loss of ...

On September 26, 2025, Fractyl Health announced positive results from the REMAIN-1 Midpoint Cohort, showing that its Revita therapy helped maintain weight loss in patients who discontinued GLP-1 drugs ...

Viking Therapeutics' shares plunged after mixed phase 2 results for a GLP-1 candidate. However, the data wasn't nearly as bad ...

GLP-1 initiation was common among patients who underwent bariatric surgery, especially sleeve gastrectomy vs Roux-en-Y gastric bypass.

A Japanese study links external eating patterns to weight loss and glycemic improvements with glucagon-like peptide-1 receptor agonists.

Pilot study met key 3-month efficacy endpoint with strong statistical significance (p=0.014); Revita-treated patients lost an ...

GLP-1 RA Effects Beyond Glycaemic Control A RECENT network meta-analysis suggests that GLP-1 receptor agonists (GLP-1 RAs) ...

A new large-scale study came to the conclusion that weight-loss surgery gives people with type 2 diabetes and obesity a ...

Coya Therapeutics Inc. (NASDAQ:COYA) on Tuesday announced results from a study designed to evaluate the effects of COYA 303 (LD IL-2 and GLP-1RA), Coya's investigational biologic combination, in an in ...

Pfizer's purchase of Metsera marks a significant step in enhancing its pipeline of GLP-1 medications. With Metsera’s investigational drugs, such as MET-097i and MET-233i, Pfizer is positioning itself ...